Oxford Biomedica to support Boehringer Ingelheim’s LENTICLAIR 1 trial
OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled ...
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
realestateasia4 天
Why new home sales surged to a 15-year high in Singapore’s city fringe area in Q4
In a recent report, OrangeTee noted that many new homes were sold in the city fringe area in the fourth quarter of 2024, ...